Shawn Flanagan

Shawn Flanagan is a seasoned professional in clinical pharmacology and translational development, currently serving as the SVP of Clinical Pharmacology & Translational Development at Elion Therapeutics since July 2025. Previously, Flanagan held the position of Vice President of Clinical Pharmacology & Early Development at Cidara Therapeutics, where significant contributions included leading clinical development initiatives and developing dose justification strategies for antifungal prophylaxis. Flanagan's extensive experience encompasses roles at various pharmaceutical companies, including Executive Director at Esperion Therapeutics, Sr. Principal Scientist at Merck, and Senior Director at Cubist and Trius Therapeutics, focusing on clinical pharmacokinetics, regulatory submissions, and program strategy. Flanagan's career began with a PhD in Pharmaceutical Chemistry from the University of California, San Francisco, leading to impactful roles in drug development and regulatory interactions, including key contributions to the FDA Advisory Committee for CONTRAVE.